全文获取类型
收费全文 | 452篇 |
免费 | 52篇 |
国内免费 | 24篇 |
专业分类
儿科学 | 55篇 |
妇产科学 | 4篇 |
基础医学 | 30篇 |
口腔科学 | 8篇 |
临床医学 | 43篇 |
内科学 | 91篇 |
皮肤病学 | 6篇 |
神经病学 | 19篇 |
特种医学 | 50篇 |
外科学 | 57篇 |
综合类 | 43篇 |
预防医学 | 48篇 |
眼科学 | 5篇 |
药学 | 38篇 |
肿瘤学 | 31篇 |
出版年
2024年 | 2篇 |
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 10篇 |
2019年 | 11篇 |
2018年 | 17篇 |
2017年 | 15篇 |
2016年 | 9篇 |
2015年 | 13篇 |
2014年 | 20篇 |
2013年 | 21篇 |
2012年 | 11篇 |
2011年 | 10篇 |
2010年 | 18篇 |
2009年 | 15篇 |
2008年 | 17篇 |
2007年 | 26篇 |
2006年 | 15篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 8篇 |
2002年 | 9篇 |
2001年 | 12篇 |
2000年 | 9篇 |
1999年 | 6篇 |
1998年 | 26篇 |
1997年 | 20篇 |
1996年 | 22篇 |
1995年 | 10篇 |
1994年 | 23篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 10篇 |
1989年 | 8篇 |
1988年 | 15篇 |
1987年 | 6篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1973年 | 2篇 |
1971年 | 2篇 |
排序方式: 共有528条查询结果,搜索用时 15 毫秒
91.
Judith de Vos-Geelen Sandra ME Geurts Margreet van Putten Liselot BJ Valkenburg-van Iersel Heike I Grabsch Nadia Haj Mohammad Frank JP Hoebers Chantal V Hoge Paul M Jeene Evelien JM de Jong Hanneke WM van Laarhoven Tom Rozema Marije Slingerland Vivianne CG Tjan-Heijnen Grard AP Nieuwenhuijzen Valery EPP Lemmens 《World journal of gastroenterology : WJG》2019,25(47):6835-6846
BACKGROUND The management of proximal esophageal cancer differs from that of tumors located in the mid and lower part of the esophagus due to the close vicinity of vital structures. Non-surgical treatment options like radiotherapy and definitive chemoradiation(CRT) have been implemented. The trends in(non-)surgical treatment and its impact on overall survival(OS) in patients with proximal esophageal cancer are unclear, related to its rare disease status. To optimize treatment strategies and counseling of patients with proximal esophageal cancer,it is therefore essential to gain more insight through real-life studies.AIM To establish trends in treatment and OS in patients with proximal esophageal cancer.METHODS In this population-based study, patients with proximal esophageal cancer diagnosed between 1989 and 2014 were identified in the Netherlands Cancer Registry. The proximal esophagus consists of the cervical esophagus and the upper thoracic section, extending to 24 cm from the incisors. Trends in radiotherapy, chemotherapy, and surgery, and OS were assessed. Analyses were stratified by presence of distant metastasis. Multivariable Cox proportional hazards regression analyses was performed to assess the effect of period of diagnosis on OS, adjusted for patient, tumor, and treatment characteristics.RESULTS In total, 2783 patients were included. Over the study period, the use of radiotherapy, resection, and CRT in non-metastatic disease changed from 53%,23%, and 1% in 1989-1994 to 21%, 9%, and 49% in 2010-2014, respectively. In metastatic disease, the use of chemotherapy and radiotherapy increased over time. Median OS of the total population increased from 7.3 mo [95% confidence interval(CI): 6.4-8.1] in 1989-1994 to 9.5 mo(95%CI: 8.1-10.8) in 2010-2014(logrank P 0.001). In non-metastatic disease, 5-year OS rates improved from 5%(95%CI: 3%-7%) in 1989-1994 to 13%(95%CI: 9%-17%) in 2010-2014(logrank P 0.001). Multivariable regression analysis demonstrated a significant treatment effect over time on survival. In metastatic disease, median OS was 3.8 mo(95%CI:2.5-5.1) in 1989-1994, and 5.1 mo(95%CI: 4.3-5.9) in 2010-2014(logrank P = 0.26).CONCLUSION OS significantly improved in non-metastatic proximal esophageal cancer, likely to be associated with an increased use of CRT. Patterns in metastatic disease did not change significantly over time. 相似文献
92.
93.
94.
Anita CG Chua Borut Klopcic Ian C Lawrance John K Olynyk Debbie Trinder 《World journal of gastroenterology : WJG》2010,16(6):663-672
The carcinogenic potential of iron in colorectal cancer(CRC) is not fully understood.Iron is able to undergo reduction and oxidation,making it important in many physiological processes.This inherent redox property of iron,however,also renders it toxic when it is present in excess.Iron-mediated generation of reactive oxygen species via the Fenton reaction,if uncontrolled,may lead to cell damage as a result of lipid peroxidation and oxidative DNA and protein damage.This may promote carcinogenesis through incr... 相似文献
95.
Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma 下载免费PDF全文
96.
Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups 下载免费PDF全文
Veronique Minard‐Colin David Walterhouse Gianni Bisogno Helene Martelli James Anderson David A. Rodeberg Andrea Ferrari Meriel Jenney Suzanne Wolden Gianluca De Salvo Carola Arndt Johannes H. M. Merks Soledad Gallego Dominique Schwob Christine Haie‐Meder Christophe Bergeron Michael C. G. Stevens Odile Oberlin Douglas Hawkins 《Pediatric blood & cancer》2018,65(9)
1 Background
Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed.2 Procedure
From 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n = 160), 2.7 for uterus corpus (n = 26), and 13.5 for uterus cervix (n = 51). Twenty‐eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG).3 Results
Ten‐year event‐free (EFS) and overall survival (OS) were 74% (95% CI, 67–79%) and 92% (95% CI, 88–96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P = 0.08), there was no difference in OS (94% without RT vs. 89% with RT; P = 0.18). Local control using brachytherapy was excellent (93%). Fifty‐one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery.4 Conclusions
About half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy. 相似文献97.
M. A. Gillentine L. N. Berry R. P. Goin-Kochel M. A. Ali J. Ge D. Guffey J. A. Rosenfeld V. Hannig P. Bader M. Proud M. Shinawi B. H. Graham A. Lin S. R. Lalani J. Reynolds M. Chen T. Grebe C. G. Minard P. Stankiewicz A. L. Beaudet C. P. Schaaf 《Journal of autism and developmental disorders》2017,47(3):549-562
Chromosome 15q11q13 is among the least stable regions in the genome due to its highly complex genomic architecture. Low copy repeat elements at 15q13.3 facilitate recurrent copy number variants (CNVs), with deletions established as pathogenic and CHRNA7 implicated as a candidate gene. However, the pathogenicity of duplications of CHRNA7 is unclear, as they are found in affected probands as well as in reportedly healthy parents and unaffected control individuals. We evaluated 18 children with microduplications involving CHRNA7, identified by clinical chromosome microarray analysis (CMA). Comprehensive phenotyping revealed high prevalence of developmental delay/intellectual disability, autism spectrum disorder, and attention deficit/hyperactivity disorder. As CHRNA7 duplications are the most common CNVs identified by clinical CMA, this study provides anticipatory guidance for those involved with care of affected individuals. 相似文献
98.
99.